In today’s briefing:
- STAAR Surgical Faces Shareholder Activism and Alcon’s Revised Bid Amidst China Sales Recovery and Strategic Uncertainty
STAAR Surgical Faces Shareholder Activism and Alcon’s Revised Bid Amidst China Sales Recovery and Strategic Uncertainty
- STAAR Surgical’s China sales rebounded to 60% of normalized levels, supporting activist investors’ opposition to Alcon’s takeover offer.
- Alcon increased its bid to $30.75/share, but Broadwood and Yunqi rejected it, citing inadequate shareholder value.
- Shareholder vote on Alcon’s offer is scheduled for December 19, with potential board reshuffle if takeover is blocked.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
